Literature DB >> 17403025

Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastin) injections.

Stefan Mennel, Josep Callizo, Jörg C Schmidt, Carsten H Meyer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17403025     DOI： 10.1111/j.1600-0420.2007.00926.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN： 1395-3907


× No keyword cloud information.
  10 in total

Review 1.  [Intravitreal injection. Monitoring to avoid postoperative complications].

Authors:  C H Meyer; F Ziemssen; H Heimann
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

2.  Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis).

Authors:  David Sarraf; Anthony Joseph; Ehsan Rahimy
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

Review 3.  The treatment of wet age-related macular degeneration.

Authors:  Antonia M Joussen; Norbert Bornfeld
Journal:  Dtsch Arztebl Int       Date:  2009-05-01       Impact factor: 5.594

Review 4.  Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab.

Authors:  C H Meyer; F G Holz
Journal:  Eye (Lond)       Date:  2011-04-01       Impact factor: 3.775

5.  Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells.

Authors:  Alexa Karina Klettner; Marie-Luise Kruse; Tim Meyer; Daniela Wesch; Dieter Kabelitz; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-14       Impact factor: 3.117

6.  Intracellular bevacizumab reduces phagocytotic uptake in RPE cells.

Authors:  Alexa Klettner; Friederike Möhle; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-19       Impact factor: 3.117

7.  [Retinochoroidopathy after intravitreal anti-VEGF treatment].

Authors:  M Maier; N Feucht; I Lanzl; P Kook; C P Lohmann
Journal:  Ophthalmologe       Date:  2009-08       Impact factor: 1.059

8.  [Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress].

Authors:  D Kook; A Wolf; A S Neubauer; C Haritoglou; S G Priglinger; A Kampik; M W Ulbig
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

Review 9.  Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Authors:  Focke Ziemssen; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Martin S Spitzer
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

10.  Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany.

Authors:  Nikolaus Feucht; Huebner Matthias; Chris P Lohmann; Mathias Maier
Journal:  Clin Ophthalmol       Date:  2008-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.